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Abstract 
The proteasome inhibitor bortezomib simultaneously renders tumor cells sensitive to killing 
by natural killer (NK) cells and resistant to killing by tumor-specific T cells. Here, we show 
that b-AP15, a novel inhibitor of proteasome deubiquitinating activity, sensitizes tumors to 
both NK and T cell-mediated killing. Exposure to b-AP15 significantly increased the 
susceptibility of tumor cell lines of various origins to NK (p<0.0002) and T cell (p=0.02) –
mediated cytotoxicity. Treatment with b-AP15 resulted in increased TRAIL [tumor necrosis 
factor-related apoptosis-inducing ligand] receptor-2 expression (p=0.03) and decreased cFLIP 
expression in tumor cells in vitro. In tumor-bearing SCID/Beige mice, treatment with b-AP15 
followed by infusion of either human NK cells or tumor-specific T cells resulted in a 
significantly delayed tumor progression compared with mice treated with NK cells (p=0.006), 
T cells (p<0.0001), or b-AP15 alone (p=0.003). Combined infusion of NK and T cells in 
tumor-bearing BALB/c mice following treatment with b-AP15 resulted in a significantly 
prolonged long-term survival compared with mice treated with b-AP15 and NK or T cells 
(p≤0.01). Our findings show that b-AP15-induced sensitization to TRAIL-mediated apoptosis 
could be used as a novel strategy to augment the anti-cancer effects of adoptively infused NK 
and T cells in patients with cancer. 
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Précis: Treatment with the proteasome deubiquitinating inhibitor b-AP15 sensitizes tumor 
cells to NK and T cell –mediated killing in vitro and in vivo. Infusion of both NK and T cells 
following b-AP15 treatment prolongs survival in tumor-bearing hosts. 
Introduction 
Adoptive T cell therapy elicits long-lasting clinical responses in patients with malignant 
metastatic melanoma [1]. However, randomized clinical trials have failed to find similar 
results in other malignancies [2]. In addition the adoptive infusion of autologous natural killer 
(NK) cells has yet to show clinical benefit in treating cancer patients [3]. This clinical failure 
may be in part due to sustained immunological selection pressure on tumor cells resulting in 
the development of tumor escape variants that are effectively invisible to the immune system. 
One of the most frequent immune escape strategies tumors use to avoid being detected by 
cytotoxic T cells is down-regulation of MHC class I [4,5]. As a result, individual cells may 
display differential expression of MHC class I within a growing tumor mass [6]. While MHC 
class I positive tumor cells are targeted by tumor-specific T cells, MHC class I negative tumor 
cells can be killed by NK cells due to lack of ligation of inhibitory Killer Immunoglobulin-
like receptors (KIRs) on NK cells. Simultaneous adoptive cell therapy with tumor-specific T 
cells and NK cells may therefore offer a strategy to generate broader anti-tumor responses 
compared with infusion of NK or T cells as a monotherapy. Such combined therapy could 
potentially result in improved clinical responses.  
Besides secreting lytic granules, T and NK cells ligate death receptors on tumor cells to 
induce apoptosis [7-10]. We and others have recently demonstrated that exposure to the 
proteasome inhibitor bortezomib significantly up-regulated the expression of death receptors 
to TNF-related apoptosis-inducing ligand (TRAIL) [11-13]. However, bortezomib-treated 
tumors sensitized to NK cell apoptosis simultaneously acquire resistance to antigen-specific T 
cells [14]. As bortezomib predominantly inhibits the chymotryptic-like activity of the 20S 
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proteasome [15], impaired antigen processing and presentation prevent tumor-specific T cells 
from killing bortezomib-treated tumors.  
We have recently identified the small molecule b-AP15 as a novel inhibitor of proteasome 
deubiquitinating activity [16]. Cells treated with b-AP15 accumulate polyubiquitinated 
proteins, with similar kinetics to cells treated with bortezomib. b-AP15-induced proteasome 
inhibition was concomitant with the up-regulation of apoptotic markers and the accumulation 
of cell-cycle regulatory proteins, leading to cell cycle arrest and apoptosis independent of the 
tumor suppressor p53 or overexpression of the BCL2 oncogene, which are implicated in 
bortezomib resistance. 
In the present study we sought to investigate whether inhibition of proteasome 
deubiquitinating activity sensitizes tumors to both T and NK cell-mediated killing. Similarly 
to bortezomib, we found that treatment with sub-apoptotic doses of b-AP15 resulted in an 
increased surface expression of TRAIL-R2 and decreased expression of cFLIP in tumor cells. 
As a consequence, b-AP15-treated tumors displayed an increased sensitivity to killing by both 
NK and T cells in vitro. Furthermore, significantly increased survival times were observed in 
mice treated with b-AP15 followed by combined infusion of syngeneic NK and tumor-
specific T cells relative to mice treated with b-AP15 followed by infusion of either syngeneic 
NK or tumor-specific T cells.  
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Materials and methods 
Human NK and T cell culture 
Human NK cells were isolated from peripheral blood mononuclear cells (PBMC) of healthy 
donors and melanoma patients (ethical permit dnr #2009/848-3) by negative immuno-
magnetic bead depletion (Miltenyi Biotech, BergischGladbach, Germany). Purified NK cells 
(≥95%) were expanded with 25 Gy irradiated autologous PBMC (feeder cells) at a 1:20 cell 
ratio (NK: feeder) in X-VIVO 20 media (Lonza, Verviers, Belgium) supplemented with 10% 
heat-inactivated human AB serum (Karolinska Hospital, Stockholm, Sweden) and 500 U/ml 
recombinant human interleukin-2 (IL-2) (Novartis pharma GmbH, Nurnberg, Germany). 
Fresh medium containing 500 U/ml IL-2 was added on days 5, 8 and 11, and NK cells were 
tested for cytotoxicity or infused into mice on days 11-14 of expansion. Contamination of 
CD3 positive T cells was <1%. 
Tumor specific T cells were isolated from tumor biopsies from HLA-A2 positive melanoma 
patients. Biopsies were manually dissected into small pieces and transferred to 24-well plates 
followed by incubation with 6,000 U/ml of IL-2 in X-vivo 20 medium supplemented with 5% 
AB serum for six days. Tumor infiltrating lymphocytes were screened for antigen-specificity 
by intracellular staining for interferon-gamma (IFNγ) and IL-2 (Biolegend, San Diego, USA) 
against T2 cells pulsed with HLA-A2 binding melanoma-associated peptides gp100, MAGE-
1, MAGE-3, Survivin and Mart-1 (Genecust, Dudelang, Luxembourg). 8.4% of T cells 
stained positive for IFNγ and IL-2 after co-culture with Mart1 (ELAGIGILTV)-pulsed T2 cells, but 
not against any of the other peptides. These TILs were expanded in X-vivo 20 medium 
supplemented with 5% AB, 500 U/ml IL-2 and 50 ng/ml anti-CD3 antibody (Janssen-Cilag, 
Sollentuna, Sweden) and irradiated (40 Gy) allogeneic PBMC. Medium supplemented with 
500 U/ml of IL-2 was replenished on days 5 and 8 of culture. Purity of CD3 positive T cells 
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was ≥94% with <1% contamination of CD56 positive NK cells. Expanded NK and T cells 
were tested against K562 cells (Supplementary Fig. 1A). T cells were tested negative against 
the HLA-A2 negative tumor cell line EST115 (Table 1). 
Murine NK and T cell culture 
Murine NK cells were isolated from BALB/c splenocytes by negative bead depletion (MACS, 
Miltenyi Biotech) and cultured in 96-U bottom plates in RPMI1640 medium supplemented 
with 10% FCS, 50 μM Beta-mercapethanol, 25 ug/ml gentamycin, 2 mM L-glutamine, 1% 
NEAA (Invitrogen, Eugene, Oregon, USA) and 500 U/ml of human IL-2 for 5 days. Murine 
tumor-specific T cells were generated by whole tumor cell vaccination. Briefly, BALB/c mice 
received three weekly intraperitoneal (i.p) injections of 1x10
6
 irradiated (10,000 Rad) D2F2 
breast cancer cells. Spleen and lymphnodes were collected and re-stimulated with irradiated 
(5,000 Rad) D2F2 and recombinant human IL-2 (100 U/ml) in vitro for four days. T cells 
were tested for tumor reactivity in a 51Cr-release assay against D2F2 cells, YAC-1 cells, and 
RENCA cells. Generated T cells tested negative against RENCA (Table 1) and YAC-1 
tumors (Supplementary Fig. 1B).  
Tumor cell lines 
Tumor cell lines include: EST152, EST027, EST066, EST049, EST025, JuSo (human 
melanoma) MDA453, MCF-7, MDA484 (human breast cancer), PC3, DU145 (human 
prostate cancer), J82, RT4 (human bladder cancer), A498, JOHW (kidney cancer), HCT116 
(colon cancer), SKOV3, HeLa (ovarian cancer), BJ1 (normal fibroblast), and K562. Murine 
cell lines include: D2F2 (breast cancer), RENCA (renal cancer), B16 (melanoma) and YAC-1 
(lymphoma). STR Identifier (Applied Biosystems, UK) was used to verify the origin of 
human tumor cell lines; EST152, EST027, EST066, EST049, EST025, MDA453, MCF-7, 
MDA484, J82, HCT116, HeLa and SKOV3. The EST melanoma cell lines were provided by 
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Dr. Rolf Kiessling, Karolinska Institutet through the IPD-ESTDAB Database 
(http://www.ebi.ac.uk/ipd/estdab/directory.html). All cell lines were maintained in RPMI1640 
media with 10% fetal calf serum (Invitrogen, Eugene, Oregon, USA), 50 U/ml penicillin, and 
50 mg/ml streptomycin (Invitrogen).  
Reagents and antibodies  
Tumor cells were treated in vitro with 1 µM of b-AP15 (3,5-bis[(4-nitrophenyl)methylidene]-
1-prop-2-enoylpiperidin-4-one, Oncotargeting AB Uppsala, Sweden) for 3 hours before 
analysis for phenotype by flow cytometry or susceptibility to killing in cytotoxicity assays. 
J82 and EST027 cells were treated with 20 nM of bortezomib (Millennium Pharmaceuticals, 
Inc.) for 20 hours before testing in cytotoxicity assays. To evaluate TRAIL- or Fas ligand –
mediated cytotoxicity of human tumors, recombinant TRAIL or Fas ligand (Peprotech, 
London, UK) was added to cells in cytotoxicity assays at 100 ng/ml and 150 ng/ml 
respectively. Concanamycin A (CMA; Sigma, Schnelldorf, Germany) was added in 
cytotoxicity assays at 100 nM to degrade perforin. Isolated and expanded NK cells and TILs 
were assessed for purity and TRAIL expression by flow cytometry after staining with 
antibodies against human CD3, CD56, CD4 and CD8, TRAIL (Biolegend). Human tumors 
were stained for TRAIL-R1, R2, R3, Fas, MICA/B and Nectin-2, MHC class I (Biolegend). 
Murine BALB/c D2F2 tumor cells were stained with TRAIL-R2 (Biolegend) before and after 
treatment with 1 µM b-AP15 for 3 hours. Apoptosis was analyzed by staining with Annexin-
V and 7-AAD (Biolegend). All flow cytometry experiments were acquired on an LSRII (BD 
Biosciences, San Jose, California, USA) and data was analyzed using FlowJo software (Tree 
Star, Ashland, USA). 
Western Blot 
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J82, JOHW, DU145, JuSo, A498, HCT116, HeLa and MCF-7 cells were treated with 1 μM of 
b-AP15 for 3 hours or left untreated. Post-treatment cells were lysed in buffer (cellLytic M, 
Sigma, St. Louis, Mo, USA) containing protease inhibitor cocktail (Sigma). Equal amount of 
protein (20 μg) from total cell lysates were resolved on NuPAGE gels, transferred to PVDF, 
blocked in 5% milk and incubated overnight incubation with rabbit anti-c-FLIP (Cell 
Signaling Technology, Beverly, MA), or mouse anti-β-actin (Sigma) antibodies. Membranes 
were incubated with HRP-linked goat anti-rabbit or anti-mouse IgG Abs (Cell Signaling 
Technology) for 1 hour at room temperature and developed by enhanced chemiluminescence 
(GE Healthcare, Fairfield, CT). The protein quantity was determined relative to β-actin and 
analyzed by ImageJ-software (National Institutes of Health, http://rsb.info.nih.gov/ij).    
Cytotoxicity and cytokine production assays 
In chromium51-release cytotoxicity assays, target cells were labeled with 51Cr (50 μCi) 
(PerkinElmer, Groningen, The Netherlands) and seeded in 96 U-bottom plates in triplicates. 
Human or murine NK or T cells were added to target cells at different E:T ratios. Following 
18 hour incubation, 25 μl of supernatant was transferred onto Luma plates (PerkinElmer) and 
analyzed using MicroBeta scintillation (TRILUX 1450) counter (PerkinElmer). For 
intracellular staining of IFNγ, 10,000 tumor cells were plated with 20,000-200,000 NK or T 
cells in a 96 U-bottom plate and incubated for 6 hours. Staining was performed following the 
manufacturer’s instructions (BD Biosciences). Where indicated, cytotoxicity assays were 
performed in presence of neutralizing antibodies against TRAIL (10 ug/ml), NKG2D (10 
ug/ml), Fas-ligand (10 ug/ml), DNAM-1(10 ug/ml) (Biolegend) or CMA (100 nM,).  
In vivo tumor models 
All animal experiments were performed at the Department of Microbiology, Tumor and Cell 
Biology (MTC) or the Swedish Institute for Infectious Disease Control, Karolinska Institutet 
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under approved study N42/10. SCID/beige mice were purchased from Charles River 
(Sulzfeld, Germany). SCID/Beige mice (8-12 weeks old) were injected subcutaneously (s.c) 
with J82 tumors (3x10
6
/mouse) in the right flank. When tumors were palpable (>1 mm
3
, day 
10), mice were grouped to receive either vehicle (n=4) or b-AP15 (n=4) at 2.5 mg per kg of 
body weight (i.p). The following day, mice were injected intravenously (i.v) with 2x10
6
 NK 
cells or 4x10
6 
TILs. In cytotoxicity assays, in vitro killing of untreated J82 tumors was 
approximately 2-fold higher by NK cells compared with TILs; therefore a 1:2 ratio of infused 
NK cells and TILs was used. Mice were treated for a total of three cycles, receiving injections 
of b-AP15 on days 12, 19 and 26 and cell infusions on days 13, 20, and 27 post tumor 
injection. 
To investigate the potential synergistic effect of combined NK and T cell therapy, immune 
competent male BALB/c mice were injected s.c with D2F2 cells (100,000/mouse) in the right 
flank. Alternatively, BALB/c mice were injected i.v with lentiviral-transduced luciferase 
(AMS Biotechnology, UK) D2F2 cells (100,000/mouse). Within one week, when s.c tumors 
were palpable (>5 mm
3
, day 6) or pulmonary metastases were visible by bioluminescence 
imaging (day 3), BALB/c mice were treated with either vehicle (PBS) or three weekly cycles 
of b-AP15 (2.5 mg/kg) followed by the next day infusion of NK cells (0.75-1.5x10
6
cells) 
and/or tumor-specific T cells (1-2x10
6
cells). Mice treated with the combination of both NK 
and T cells received the same number of total cells compared to mice receiving NK or T cells 
alone. Tumor progression was assessed by palpation twice weekly or by in vivo 
bioluminescence imaging. In vivo imaging was performed by injecting mice with luciferin (3 
ug/mouse, i.p). Mice were imaged the IVIS camera platform (Caliper LifeSciences Benelux & 
Nordic, Belgium). The in vivo experiments were repeated twice with 4-6 mice per treatment 
group.    
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Statistical analysis 
All statistical analyses were performed using GraphPad Prism 5.0 software. The in vitro data 
were analyzed by paired or unpaired t-test and in vivo data were analyzed using unpaired t-
test, two-way ANOVA and Log-rank (Mantel-Cox) test. Correlation tests were performed 
using Pearson’s correlation test.  p-values below 0.05 were considered statistically significant 
between treatment groups.     
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Results 
Increased TRAIL-mediated killing of b-AP15 treated tumors 
b-AP15-treated J82 tumor cells were stained with Annexin V to evaluate the level of 
apoptosis. No change in the percentage of dead cells was observed in cells treated with 1 µM 
b-AP15 for 3 hours compared with untreated cells (untreated 7±4%, b-AP15 8±4%). Under 
these conditions, the expression of TRAIL-R2 was significantly up-regulated (p=0.03) 
compared with untreated controls in a panel of tumor cell lines (J82, DU145, A498, HCT116, 
HeLa, MDA453) (Fig. 1A). In contrast, no significant change in expression of Fas was 
observed in these cell lines following treatment with b-AP15 (Fig. 1B). Additionally, no 
changes were observed in the expression of TRAIL-R1, TRAIL-R3, MHC class I, MICA/B, 
and Nectin-2 following treatment of J82 cells with b-AP15 (Supplementary Fig. 1C). In 
contrast, expression of cFLIP was down-regulated in J82 cells following exposure to b-AP15 
(Supplementary Fig. 1D). When tumor cell lines were examined for susceptibility to TRAIL-
induced apoptosis, b-AP15 pre-treatment resulted in significantly increased TRAIL-mediated 
killing in several tumor cell lines including HCT116, A498, J82, RT4, MDA453, and DU145 
(p=0.002) (Fig. 1C). Killing by recombinant FasL was higher in b-AP15 treated A498 cells 
compared with untreated cells. However, no increase in FasL-mediated killing was observed 
in any of the other cells lines after treatment with b-AP15 (p=0.07) (Fig. 1D).  
 
b-AP15 sensitizes tumor cells to TRAIL-mediated NK- and T- cell killing in vitro 
Upon activation with IL-2, human NK and T cells express TRAIL (Supplementary Fig. 2A). 
We next investigated whether b-AP15-treated tumor cells would be more sensitive to killing 
by activated NK and T cells. Indeed, human tumor cells treated with b-AP15 were 
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significantly more sensitive to killing by NK (p<0.0002) and tumor (Mart1) specific T cells 
(p=0.02) (Fig. 2A and Table 1). In contrast to our previous findings, where tumor cell lines 
pretreated with the proteasome inhibitor bortezomib were resistant to T cell-mediated killing 
[14], b-AP15 pretreated J82 and EST027 cells were highly sensitized to T cell-mediated 
killing relative to untreated or bortezomib treated cells (Supplementary Fig.2B). Importantly 
b-AP15 did not sensitize fibroblasts to NK cell-mediated killing (Table 1).  
To confirm if the underlying mechanism of killing was dependent on TRAIL-R2 signaling, 
cytotoxicity assays were performed in the presence of neutralizing antibodies. Both NK and T 
cell–mediated killing of b-AP15-treated human tumors was significantly reduced in the 
presence of neutralizing antibodies to TRAIL. Although overall cytotoxicity was reduced in 
presence of the perforin inhibitor concanamycin A and neutralizing antibodies to Fas ligand, 
b-AP15 still sensitized tumors to NK- and T-cell-mediated killing in presence of these 
inhibitors (Fig. 2B). Furthermore, no significant reduction in killing were observed in 
presence of neutralizing antibodies to NKG2D or DNAM-1 between untreated and b-AP15 
treated tumor cells (Supplementary Fig. 2C). 
Given that treatment with b-AP15 results in increased TRAIL-R2 expression and decreased 
cFLIP expression, we next addressed which of these events are required for b-AP15-mediated 
sensitization to NK cell killing. An overall positive correlation in NK cell-mediated killing 
and expression of TRAIL-R2 was observed in tumor cell lines before and after treatment with 
b-AP15 (p=0.006). Although an average decrease of 56%±11% in the expression of cFLIP 
was observed following treatment with b-AP15 in several cell lines (J82, JOHW, JuSo, and 
HeLa), no significant overall correlation was found between the cFLIP expression and 
sensitivity to NK cell-mediated killing (Fig. 3A). Furthermore, increased NK cell-mediated 
killing was only observed in individual cell lines where expression of TRAIL-R2 was 
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significantly increased. In contrast, NK cell-mediated killing was independent of decreased 
cFLIP expression after b-AP15 treatment (Fig. 3B). 
 
b-AP15 sensitizes tumor cells to adoptively infused NK and T cells in vivo.  
To investigate the therapeutic impact of b-AP15 in sensitizing tumors to human NK and T cell 
–mediated killing, tumor-bearing immune-deficient SCID/Beige mice were pre-treated with 
b-AP15 and thereafter infused with either NK or tumor-specific T cells. Treatment with b-
AP15, NK, or T cells alone resulted in a significantly delayed tumor progression compared 
with untreated mice (p<0.002; data not shown). Furthermore, a further delay in tumor 
progression was observed upon infusions of NK or T cells in mice pre-treated with b-AP15 
compared with mice treated with b-AP15, T, or NK cells alone (p<0.01) (Fig. 4A, B, and C).  
We next asked whether combined infusion of both NK and T cells would result in further 
delayed tumor progression in b-AP15 treated mice. In vitro, treatment with b-AP15 resulted in 
a minor up-regulation of TRAIL-R2 expression. Nevertheless, this increase in expression was 
sufficient to sensitize D2F2 tumor cells to NK and T cell –mediated killing. Furthermore, the 
level of murine NK cell and T cell killing of b-AP15-treated tumor cells was reduced in the 
presence of neutralizing antibodies to TRAIL (Supplementary Fig. 3A, B and C). In addition, 
RENCA, but not B16 melanoma tumor cell lines were efficiently killed by NK cells following 
exposure to b-AP15 compared with untreated tumor cells (Table 1). Moreover murine NK and 
tumor specific T cells displayed elevated IFNγ production when co-cultured with b-AP15 
treated D2F2 cells compared with those co-cultured with untreated D2F2 tumors (data not 
shown).  
In mice bearing s.c implanted syngeneic D2F2 tumors, treatment with b-AP15, NK cells, or T 
cells alone did not result in reduced tumor burden compared with untreated tumor-bearing 
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BALB/c mice. After three infusions, the median tumor sizes were 33411 (untreated mice), 
326 91 (b-AP15 treated mice), 34084 (NK cell treated mice), 26023 (T cell treated mice), 
and 36325 (NK cell + T cell treated mice). However, compared with mice treated with b-
AP15 alone or NK+T cell treated mice without b-AP-15, treatment with b-AP15 followed by 
infusion of both NK and T cells resulted in significantly reduced tumor burden in mice 
bearing s.c tumors (p≤0.01; Fig. 5A).  
In addition bioluminescence imaging of mice implanted with luciferase expressing D2F2 
cells, showed a significant decrease in tumor burden in mice pre-treated with b-AP15 and co-
infused with NK- and T-cells (p≤0.002, Fig. 5B and C). Similarly to the subcutaneous model, 
no change in tumor burden was observed after treatment with b-AP15, NK cells, T cells, or T 
cells and NK cells alone compared with untreated mice (data not shown). Moreover, the 
combined infusion of NK and T cells resulted in significantly prolonged long-term survival in 
mice bearing i.v tumors compared with mice receiving b-AP15 and NK cells (p=0.001) or b-
AP15 and T cells (p=0.001) (Fig. 5D).  
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Discussion 
Here we demonstrate that inhibition of proteasome deubiquitinating activity leads to 
sensitization of tumor cells to NK and T cell –mediated killing, and that the mechanism of 
sensitization centers upon up-regulation of TRAIL-R2. Several chemotherapeutical agents 
have been shown to increase TRAIL receptor expression on tumor cells [17,18]. We and 
others previously demonstrated that treatment with the proteasome inhibitor bortezomib 
increases TRAIL-R2 expression on tumor cells resulting in an increased killing by activated 
NK cells via TRAIL in vitro [12,19]. Whether bortezomib can sensitize tumor cells to T cell-
mediated killing is less clear. Bortezomib was recently shown to inhibit NF-κB activity and 
restore MART-1 expression and pro-apoptotic signaling, resulting in sensitization of 
melanoma tumors to killing by TCR-engineered CTLs [20]. We have demonstrated that 
bortezomib-treated tumor cells are resistant to killing by tumor-specific TILs due to impaired 
antigen processing and presentation [14]. Differences in T cell preparation and source may 
account for these differences. In accordance with our previous findings, we show that 
treatment with bortezomib results in increased NK but abrogated T cell-mediated killing of 
tumor cells. However, the same tumor cells were rendered sensitive to killing by both NK and 
T cells following exposure to the proteasome deubiquitinatinase inhibitor b-AP15. b-AP15 
inhibits the deubiquitinating activity of the regulatory 19S particle of the proteasome resulting 
in impaired degradation of cellular proteasome substrates [16]. However, unlike bortezomib 
the proteolytic activities of the 20S core proteasome is not inhibited, thus immunoproteasome 
processing and presentation of antigenic peptides to T cells is not expected to be impaired 
[16]. Therefore, we hypothesized that b-AP15 may enhance NK cell killing in a manner 
similar to bortezomib, but without dampening antigen processing and T cell-mediated killing.  
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Overall, b-AP15 induced up-regulation of TRAIL-R2 and down-regulation of cFLIP in 
human tumor cell lines in vitro. We found that up-regulation of TRAIL-R2, rather than down-
regulation of cFLIP, was associated with b-AP15-induced sensitization to NK cell-mediated 
killing. We previously demonstrated that the amplitude of NK cell-mediated lysis positively 
correlated with the degree of induction of TRAIL-R2 expression following treatment with 
bortezomib [19]. Several studies have demonstrated that down-regulation of cFLIP in tumor 
cells is required for sensitization to TRAIL-mediated killing [21,22]. In contrast, Ganten et al. 
showed that proteasome inhibition with MG132 sensitized hepatocellular carcinoma cells 
despite high levels of cFLIP [23].  
Although NK and T cell –mediated killing of b-AP15 treated tumor cells was reduced in 
presence of neutralizing antibodies to TRAIL, killing was also reduced in the presence of 
neutralizing antibodies to Fas ligand or CMA. Therefore, we cannot exclude that b-AP15 
sensitizes tumor cells partly to Fas ligand and perforin-mediated killing. This interpretation 
would be consistent with the report by Hallett et al. that treatment with proteasome inhibitors 
can sensitize tumor cells not only to TRAIL-mediated killing, but also to killing via Fas 
ligand in vitro [24].  
We have previously demonstrated that treatment with b-A15 results in reduced metastases and 
tumor growth [16]. Similarly, in this study we observed delayed tumor progression (J82 
bladder cancer) in immune deficient SCID/Beige mice upon weekly treatment with b-AP15 
compared to untreated mice. Infusion of either NK or T cells significantly delayed tumor 
progression in tumor-bearing SCID/Beige mice following pre-treatment with b-AP15 relative 
to mice receiving b-AP15 only. However, we did not observe any delay in tumor progression 
in immune competent BALB/c mice after infusion of NK or T cells or after treatment with b-
AP15. The discrepancy in results between SCID/Beige and BALB/c mice may be due to the 
rapid growth rate of the syngeneic D2F2 tumors (day 21; 359±27 mm
3
) compared with the 
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J82 tumor xenografts (day 20; 12.5±1.5 mm
3
). In addition, D2F2 tumors could be less 
sensitive to treatment due to the infusion of fewer lymphocytes (BALB/c; 0.75-2x10
6
, 
SCID/Beige; 2-4x10
6
) in this model.  
Given that tumor cells within a tumor mass have a variable expression of MHC class I [6], 
combined adoptive cell therapy with NK and tumor-specific T cells may result in better 
clinical responses compared with infusion of NK or T cells alone. However, several studies 
have demonstrated that NK and T cells may counteract each other. NK cells play an important 
role in maintaining immune homeostasis by regulating expansion of activated T cells through 
p21-mediated cell cycle arrest [25]. Olson et al. demonstrated that NK cells can inhibit and 
kill autologous alloreactive T cells [26]. Furthermore, activated T cells can inhibit NK cell-
mediated tumor rejection in mice [27]. To investigate whether combined infusion of NK and 
T cells would result in synergistic anti-tumor effects, tumor-bearing BALB/c mice were 
treated with b-AP15 followed by infusion of syngeneic NK and/or T cells. Following b-AP15 
treatment, infusion of both NK and T cells showed a significantly reduced tumor burden 
compared with mice treated with either NK or T cells. The reduced tumor burden in b-AP15 
treated mice receiving a combined infusion of NK and T cells resulted in a significantly 
extended survival. 
Several clinical studies have evaluated TRAIL receptor targeting in solid tumors. These 
studies concluded that TRAIL targeting needs to be combined with chemotherapy to generate 
objective clinical response rates [28-30]. Combined therapy with drugs like b-AP15 and 
adoptive cell therapy may have additional benefits over the use of combining 
immunosensitizing drugs and agonistic monoclonal antibodies against TRAIL or recombinant 
TRAIL for several reasons. The half-life of anti-TRAIL receptor antibodies and recombinant 
TRAIL is approximately 17 days and less than one hour respectively [31]. Adoptively 
transferred T and NK cells can be detected several months after infusion potentially resulting 
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in sustained anti-tumor effects [3,32]. Our results indicate that following exposure to b-AP15, 
tumor cells remained sensitive to NK cell killing for 72 hours in vitro, thus providing a 
relatively long therapeutic window for NK cell therapy (data not shown). Infused 
lymphocytes upon tumor interaction, produce pro-inflammatory cytokines that contribute to 
tumor eradication. Such cytokines may also recruit other inflammatory cells to the tumor 
microenvironment further heightening the anti-tumor immune response. In addition, tumor 
cells can develop resistance to TRAIL targeting by monoclonal antibodies. Since NK and T 
cells use a variety of cytolytic mechanism to induce cell death, drug-induced sensitization 
combined with adoptive cell infusion may offer a broader anti-tumor effect.  
Our findings demonstrate that inhibition of proteasome deubiquitinating activity with b-AP15 
renders tumor cells sensitive to killing by NK and T cells. Since combined therapy with NK 
and T cells increase the chances of targeting tumor cells with variable MHC class I 
expression, b-AP15 pre-treatment followed by infusion of NK and T cells may represent a 
valuable therapeutic option for the treatment of a wide variety of cancers. 
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Figure legends 
Fig. 1:  Sub-apoptotic doses of b-AP15 increase TRAIL-R2 and sensitizes human tumor 
cells to TRAIL-mediated killing in vitro 
TRAIL-R2 (A) and Fas (B) expression in untreated and b-AP15 treated [1 uM, 3 hours] J82 
(■), DU145 (□), A498 (♦), HCT116 (●), HeLa (▲) and MDA453 (○) cells. In vitro 18 hour 
51Cr-release assay of recombinant TRAIL (C) [100 ng/ml] or recombinant FasL (D) [150 
ng/ml] –mediated killing of J82 (■), DU145 (□), A498 (♦), HCT116 (●), HeLa (▲) and 
MDA453 (○) tumor cells (n=2). Statistical analysis of mean fluorescence intensity (MFI) of 
TRAIL-R2 expression (n=2); was performed by student’s paired T-test (mean+SEM). n= 
numbers of replicates.  
Fig. 2: b-AP15 sensitizes human tumor cell lines to NK and T cell –mediated killing via 
TRAIL.  
A) Human tumor cell lines J82, MDA453, HCT116, EST152, and EST027 were treated with 
1 uM b-AP15 for 3 hours and tested for susceptibility to killing by human NK cells and T 
cells in an 18 hour 51Cr-release assay (n=3). B) J82 cells were treated with b-AP15 [1 uM, 3 
hours] and tested for killing by NK or T cells in presence of neutralizing antibodies to TRAIL 
or FasL or in presence of Concanamycin A (CMA) (n=3, mean±SEM). The statistical 
significance was calculated by student’s paired T-test (mean+SEM). *p0.05. 
Fig. 3: Increased TRAIL-R2 but not decreased cFLIP expression is associated with b-
AP15-induced sensitization to NK cell-mediated killing.  
A) The Pearson’s correlation test between NK cell-mediated killing and expression of 
TRAIL-R2 or cFLIP expression was performed in tumor cell lines including J82, JOHW, 
DU145, JuSo, HeLa, A498, HCT116, MCF7, and MDA453 before and after treatment with b-
20 
 
AP15 (n=2). B) J82, JOHW and HCT116 were treated with b-AP15 or left untreated and 
tested for susceptibility to killing by human NK cells in an 18 hour 51Cr-release assay (n=3; 
mean±SEM), analyzed for TRAIL-R2 (n=2) and cFLIP expression (n=2) by flow cytometry 
and Western Blot respectively. 
Fig. 4: Adoptive infusion of human NK or T cells following b-AP15 treatment delay 
tumor progression in immune-deficient mice 
SCID/Beige mice were injected (s.c) with 3x10
6
 J82 cells and treated with b-AP15 [2.5 
mg/kg] on days 12, 19, and 26 (A) followed by infusion of either NK cells (B) or Mart-1 
specific T cells (C) on days 13, 20, and 27 post tumor injection. Tumor size was measured by 
palpation twice every week. The statistical significance was calculated by two-way ANOVA 
and p-values obtained from the interaction test between all groups compared to groups treated 
with b-AP15 and NK cells or b-AP15 and T cells. 
Fig. 5: NK- and T- cell combined therapy delay tumor progression and prolong survival 
in b-AP15 pre-treated BALB/c mice  
BALB/c mice were injected s.c (A) (n=4) or i.v (B and C) (n=5) with 0.1x10
6
 D2F2 cells and 
treated with b-AP15 on days 7, 14, and 21 or 3, 10 and 17 respectively or left untreated 
followed by the next day infusion of NK cells, T cells, or NK and T cells. (A) Tumor size on 
day 22, (B) Bioluminescence imaging on day 27 after tumor inoculation or (C) 
Bioluminescent images of two representative mice of (B). (D) Survival of tumor-bearing (i.v 
tumors) mice. The statistical significance of A) and B) was calculated by two-way ANOVA 
and p-values obtained from single row test between all groups and group receiving NK cells + 
T cells + b-AP15. Statistical analysis for survival was calculated by Log-rank (Mantel-Cox) 
test (n=6). n indicate number of mice in each treatment group. 
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Table 1. NK and T cell –mediated killing of tumor cell lines after treatment with b-
AP15. 
Human and mouse tumor cell lines of different origin were treated with b-AP15 [1 uM, 3 
hours] and tested for susceptibility to killing by NK or T cells in an 18 hour 51Cr-release 
assay at E:T ratio ranging between 0.3-3:1 or 3-9:1 respectively. p-values are calculated by 
student’s paired T-test based on fold-change values. Experiments were repeated at least twice 
for every cell line.  
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EST152 Skin  18.6 32.6 1.7 1:1 
EST027 Skin  24.0 37.3 1.5 1:1 
EST049 Skin  26.5 33.0 1.2 1:1 
EST115* Skin  32.0 39.0 1.2 2.5:1 
EST025 Skin  22.7 46.3 2.0 2.5:1 
JuSo Skin  5.0 7.0 1.4 1:1 
MDA453 Breast 8.0 17.3 2.2 1:1 
MCF-7 Breast 31.0 31.0 1.0 3:1 
MDA484 Breast 9.0 29.0 3.2 1:1 
PC3 Prostate 12.0 22.0 1.8 1.25:1 
DU145 Prostate 9.0 22.0 2.4 0.3:1 
J82 Bladder  13.6 36.0 2.6 1:1 
RT4 Bladder  29.0 38.0 1.3 1.25:1 
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A498 Kidney 13.0 24.0 2.4 1:1 
HCT116 Colon 10.3 26.6 2.6 1:1 
HEP-G Liver 16.0 32.0 2.0 1:1 
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BJ1 Fibroblast 5.0 5.0 1.0 3:1 
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A) Flow cytometry analysis of TRAIL expression on NK- and T-cells in presence or absence of [500 
U/ml] IL-2 for four days. One of two independent experiments with similar results is shown. B) J82 
and EST027 cells were either treated with b-AP15 [1 uM, 3 hours], bortezomib [Bort; 20 nM, 20 
hours] or left untreated and tested in an in vitro 18 hour 51Cr-release assay for killing by Mart-1 
specific T cells. C) J82 cells were treated with b-AP15 [1 uM, 3hours] and tested in an in vitro 18 
hour 51Cr-release assay for killing by NK cells in presence of neutralizing antibodies to NKG2D or 
DNAM-1 or T cells in presence of neutralizing antibodies to NKG2D.  
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